Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Capmatinib + Nazartinib for EGFR-Mutant NSCLC
Read More
Lung Cancer
NSCLC Year in Review Introduction
Read More
Lung Cancer
Upfront Local Radiation Therapy and First-Line TKI versus TKI Alone in Previously Untreated EGFR-Mutated Oligometastatic NSCLC
Read More
Lung Cancer
Selpercatinib Shows Antitumor Intracranial Activity in RET Fusion–Positive Patients with NSCLC and CNS Metastases
Read More
Lung Cancer
Sym015 Showed Similar Response Rate to MET TKI in Patients with METAmp/Ex14Δ NSCLC
Read More
Lung Cancer
RELAY Results: Patients with Exon 21 L858R or Exon 19 Deletion Mutations of EGFR Benefit from Ramucirumab + Erlotinib
Read More
Lung Cancer
Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations
Read More
Lung Cancer
Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations
Read More
Lung Cancer
FLAURA Trial: Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Read More
Lung Cancer
ALEX Trial: Alectinib versus Crizotinib in Treatment-Naïve Advanced ALK-Positive NSCLC
Read More
3
4
5
6
7
8
9
Page 6 of 12
Results 51 - 60 of 114